Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-04-05
Based on 364 first isolates · MED-B · Cystitis (lower UTI) · 2025-04-06 → 2026-04-05
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 82 % (78 %–85 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Klebsiella pneumoniae (6 %), Pseudomonas aeruginosa (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
89 %
88 %
n = 25
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
83 %
84 %
n = 25
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
82 %
72 %
n = 25
ciprofloxacin CIP
trend · Escherichia coli
81 %
76 %
n = 25
ceftriaxone CRO
trend · Escherichia coli
80 %
84 %
n = 25
mecillinam MEC
trend · Escherichia coli lower UTI only
80 %
84 %
n = 25
76 %
68 %
n = 25
trimethoprim TMP
trend · Escherichia coli lower UTI only
72 %
72 %
n = 25
45 %
52 %
n = 25
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
10 %
12 %
n = 25
4 %
4 %
n = 25
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
2 %
0 %
n = 25

Most likely organisms for this profile

Escherichia coli
57 %
Klebsiella pneumoniae
13 %
Enterococcus faecalis
7 %
Proteus mirabilis
7 %
Citrobacter freundii
5 %
Pseudomonas aeruginosa
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.